Treatment of primary progressive multiple sclerosis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Primary progressive multiple sclerosis (MS) is primarily a neurodegenerative phenotype of MS. It is characterized by a predominant progressive disease course that largely determines the disability progression rather than the rare early superimposed relapses. Therefore, frustratingly, the immunomodulatory and immunosuppressive approaches have failed to have any meaningful impact on the disability progression in primary-progressive MS. Some benefit can still be obtained in select patients where notable number of superimposed relapses or significant ongoing subclinical magnetic resonance imaging activity may allow for immunomodulatory agents to work. Symptomatic treatment for MS should also not be overlooked in this population for impact on quality of life. Future work will likely focus more on the remyelinating and regenerative strategies to help this group of patients. Unfortunately, the lack of any warning symptoms hampers any future prevention trial in this population. However, inferring from previous studies in secondary progressive MS, a global effort to eliminate initiation of tobacco smoking in teenagers or young adults may also delay the onset of a progressive disease course in MS.

Original languageEnglish (US)
Pages (from-to)74-78
Number of pages5
JournalSeminars in Neurology
Volume33
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Chronic Progressive Multiple Sclerosis
Multiple Sclerosis
Recurrence
Immunosuppressive Agents
Population
Young Adult
Therapeutics
Smoking
Quality of Life
Magnetic Resonance Imaging
Phenotype

Keywords

  • cigarette smoking
  • cladribine
  • glatiramer acetate
  • interferon beta-1a
  • methotrexate
  • primary progressive multiple sclerosis
  • rituximab
  • treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Treatment of primary progressive multiple sclerosis. / Kantarci, Orhun H.

In: Seminars in Neurology, Vol. 33, No. 1, 2013, p. 74-78.

Research output: Contribution to journalArticle

@article{9a6e724eae5f4b67b36d829d6e8775a0,
title = "Treatment of primary progressive multiple sclerosis",
abstract = "Primary progressive multiple sclerosis (MS) is primarily a neurodegenerative phenotype of MS. It is characterized by a predominant progressive disease course that largely determines the disability progression rather than the rare early superimposed relapses. Therefore, frustratingly, the immunomodulatory and immunosuppressive approaches have failed to have any meaningful impact on the disability progression in primary-progressive MS. Some benefit can still be obtained in select patients where notable number of superimposed relapses or significant ongoing subclinical magnetic resonance imaging activity may allow for immunomodulatory agents to work. Symptomatic treatment for MS should also not be overlooked in this population for impact on quality of life. Future work will likely focus more on the remyelinating and regenerative strategies to help this group of patients. Unfortunately, the lack of any warning symptoms hampers any future prevention trial in this population. However, inferring from previous studies in secondary progressive MS, a global effort to eliminate initiation of tobacco smoking in teenagers or young adults may also delay the onset of a progressive disease course in MS.",
keywords = "cigarette smoking, cladribine, glatiramer acetate, interferon beta-1a, methotrexate, primary progressive multiple sclerosis, rituximab, treatment",
author = "Kantarci, {Orhun H}",
year = "2013",
doi = "10.1055/s-0033-1343798",
language = "English (US)",
volume = "33",
pages = "74--78",
journal = "Seminars in Neurology",
issn = "0271-8235",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Treatment of primary progressive multiple sclerosis

AU - Kantarci, Orhun H

PY - 2013

Y1 - 2013

N2 - Primary progressive multiple sclerosis (MS) is primarily a neurodegenerative phenotype of MS. It is characterized by a predominant progressive disease course that largely determines the disability progression rather than the rare early superimposed relapses. Therefore, frustratingly, the immunomodulatory and immunosuppressive approaches have failed to have any meaningful impact on the disability progression in primary-progressive MS. Some benefit can still be obtained in select patients where notable number of superimposed relapses or significant ongoing subclinical magnetic resonance imaging activity may allow for immunomodulatory agents to work. Symptomatic treatment for MS should also not be overlooked in this population for impact on quality of life. Future work will likely focus more on the remyelinating and regenerative strategies to help this group of patients. Unfortunately, the lack of any warning symptoms hampers any future prevention trial in this population. However, inferring from previous studies in secondary progressive MS, a global effort to eliminate initiation of tobacco smoking in teenagers or young adults may also delay the onset of a progressive disease course in MS.

AB - Primary progressive multiple sclerosis (MS) is primarily a neurodegenerative phenotype of MS. It is characterized by a predominant progressive disease course that largely determines the disability progression rather than the rare early superimposed relapses. Therefore, frustratingly, the immunomodulatory and immunosuppressive approaches have failed to have any meaningful impact on the disability progression in primary-progressive MS. Some benefit can still be obtained in select patients where notable number of superimposed relapses or significant ongoing subclinical magnetic resonance imaging activity may allow for immunomodulatory agents to work. Symptomatic treatment for MS should also not be overlooked in this population for impact on quality of life. Future work will likely focus more on the remyelinating and regenerative strategies to help this group of patients. Unfortunately, the lack of any warning symptoms hampers any future prevention trial in this population. However, inferring from previous studies in secondary progressive MS, a global effort to eliminate initiation of tobacco smoking in teenagers or young adults may also delay the onset of a progressive disease course in MS.

KW - cigarette smoking

KW - cladribine

KW - glatiramer acetate

KW - interferon beta-1a

KW - methotrexate

KW - primary progressive multiple sclerosis

KW - rituximab

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84878316045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878316045&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1343798

DO - 10.1055/s-0033-1343798

M3 - Article

C2 - 23709215

AN - SCOPUS:84878316045

VL - 33

SP - 74

EP - 78

JO - Seminars in Neurology

JF - Seminars in Neurology

SN - 0271-8235

IS - 1

ER -